论文部分内容阅读
本文报道以Ommaya贮器对成人急性髓性白血病(AML)患者作脑室内化疗。28例接受了中枢神经系统(CNS)预防,7例脑膜白血病(ML)接受了治疗。接受CNS预防的28例,年龄17-73岁,中位年龄42岁,M1 13例、M23例、M32例,M47例,M53例。7例ML中1例生存期过短不能评价,余6例年龄为19-57岁,中位年龄36岁,M1、M2、M3、M5各1例,M42例。所用全身治疗的诱导方案为:Ara-C与TG 7天,联合以柔红霉素(D)或阿霉素(A)3天(TAD或TAA)。无效者以Ara-C,A再加VP-16诱导。达CR后1-2周内置入Ommaya贮器。28例接受预防性脑室内化疗,每4周用Ara-C6次,每次100mg。6例MI
This article reports the use of Ommaya reservoir for adult patients with acute myelogenous leukemia (AML) for intraventricular chemotherapy. 28 received CNS prophylaxis and 7 received meningo-leukemia (ML). 28 patients undergoing CNS prophylaxis were aged 17-73 years, with a median age of 42 years. There were 13 cases of Ml, M23 cases, M32 cases, M47 cases and M53 cases. One case of ML in 7 cases was too short to be evaluated. The remaining 6 cases were 19-57 years old, with a median age of 36 years. There were 1 case of M1, M2, M3 and M5, M42 cases. Induction regimens for systemic treatment used were: Ara-C and TG 7 days in combination with daunorubicin (D) or doxorubicin (A) for 3 days (TAD or TAA). Invalid persons were induced with Ara-C, A plus VP-16. Ommaya reservoir was placed within 1-2 weeks after CR. 28 patients received prophylactic intraventricular chemotherapy with Ara-C6 every 4 weeks for 100 mg each. 6 cases of MI